30-Oct-2026 13:05:39
AJANTA PHARMA Q2 FY27: REVENUE UP 33% YOY; PAT JUMPS 49%, US GENERICS GROW 41% & STRONG PRODUCT LAUNCH PIPELINE
• Quarterly Results: Revenue increased 33% YoY to ₹1,794 Cr, adjusted EBITDA grew 47% to ₹543 Cr and PAT surged 49% to ₹388 Cr • Margin Improvement: Adjusted EBITDA margin expanded to 30% from 27% YoY, supported by strong revenue growth and operating efficiencies • India Business: Branded generics revenue increased 16% YoY to ₹504 Cr, supported by new product launches and volume growth • US Generics Growth: Revenue surged 41% YoY to ₹484 Cr, while H1 revenue increased 49% to ₹971 Cr • US Product Pipeline: 56 active ANDAs, including 52 commercialised products, with 17 applications awaiting US FDA approval • US Filing Target: Management targets 5–6 ANDA filings; received four approvals and launched three products during H1 FY27 • India Product Launches: Launched 16 new products during Q2 FY27, strengthening its portfolio across specialty therapies • Africa Business: Branded generics revenue surged 41% YoY to ₹312 Cr, while Africa institutional revenue jumped 259% to ₹116 Cr • Asia Business: Revenue grew 18% YoY to ₹366 Cr; management indicated that earlier supply chain disruptions are normalising • Emerging Markets Expansion: Launched seven new products in H1 FY27 and plans to expand into new countries, therapies and product categories • R&D Investment: Spent ₹138 Cr on R&D during H1 FY27, representing approximately 4% of revenue, supported by over 850 scientists • Capex & Cash Flow: H1 FY27 capital expenditure stood at approximately ₹259 Cr, while operating cash flow reached ₹749.5 Cr • H1 Performance: Revenue grew 29% YoY to ₹3,420 Cr, adjusted EBITDA increased 34% to ₹997 Cr and PAT rose 40% to ₹722 Cr • Return Ratios: H1 FY27 ROCE stood at 41%, while return on net worth reached 31% • Future Growth Strategy: Focused on new product launches, market share gains, field-force productivity, geographic expansion, cost optimisation and AI-driven digitalisation
AJANTA PHARMA LIMITED